These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25690086)

  • 1. Nanotherapeutic strategies for the treatment of Alzheimer's disease.
    Gu X; Chen H; Gao X
    Ther Deliv; 2015 Feb; 6(2):177-95. PubMed ID: 25690086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential use of H102 peptide-loaded dual-functional nanoparticles in the treatment of Alzheimer's disease.
    Zhang C; Zheng X; Wan X; Shao X; Liu Q; Zhang Z; Zhang Q
    J Control Release; 2014 Oct; 192():317-24. PubMed ID: 25102404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Blood-brain barrier and Alzheimer's disease].
    Kuwahara H; Nishida Y; Yokota T
    Brain Nerve; 2013 Feb; 65(2):145-51. PubMed ID: 23399672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of the blood-brain barrier in Alzheimer's disease].
    Gosselet F; Candela P; Cecchelli R; Fenart L
    Med Sci (Paris); 2011 Nov; 27(11):987-92. PubMed ID: 22130026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease.
    Roney C; Kulkarni P; Arora V; Antich P; Bonte F; Wu A; Mallikarjuana NN; Manohar S; Liang HF; Kulkarni AR; Sung HW; Sairam M; Aminabhavi TM
    J Control Release; 2005 Nov; 108(2-3):193-214. PubMed ID: 16246446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Blood Brain Barrier and its Role in Alzheimer's Therapy: An Overview.
    Jakki SL; Senthil V; Yasam VR; Chandrasekar MJN; Vijayaraghavan C
    Curr Drug Targets; 2018; 19(2):155-169. PubMed ID: 28606049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier.
    Banks WA
    Adv Drug Deliv Rev; 2012 May; 64(7):629-39. PubMed ID: 22202501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease.
    Kulkarni PV; Roney CA; Antich PP; Bonte FJ; Raghu AV; Aminabhavi TM
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(1):35-47. PubMed ID: 20049829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotherapeutic applications of nanoparticles in Alzheimer's disease.
    Sahni JK; Doggui S; Ali J; Baboota S; Dao L; Ramassamy C
    J Control Release; 2011 Jun; 152(2):208-31. PubMed ID: 21134407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle-mediated growth factor delivery systems: A new way to treat Alzheimer's disease.
    Lauzon MA; Daviau A; Marcos B; Faucheux N
    J Control Release; 2015 May; 206():187-205. PubMed ID: 25804873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanotherapeutics for Alzheimer's disease (AD): Past, present and future.
    Fazil M; Shadab ; Baboota S; Sahni JK; Ali J
    J Drug Target; 2012 Feb; 20(2):97-113. PubMed ID: 22023651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary on "Alzheimer's disease drug development and the problem of the blood-brain barrier." Alzheimer's disease drugs: more than one barrier to breach.
    Roher AE; Kokjohn TA
    Alzheimers Dement; 2009 Sep; 5(5):437-8. PubMed ID: 19751925
    [No Abstract]   [Full Text] [Related]  

  • 13. [Nanoparticles for brain delivery of drugs or contrast agents. Application to Alzheimer's disease].
    Andrieux K; Couvreur P
    Biol Aujourdhui; 2012; 206(3):185-90. PubMed ID: 23171841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The blood-brain barrier in Alzheimer's disease: novel therapeutic targets and nanodrug delivery.
    Sharma HS; Castellani RJ; Smith MA; Sharma A
    Int Rev Neurobiol; 2012; 102():47-90. PubMed ID: 22748826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticlized System: Promising Approach for the Management of Alzheimer's Disease through Intranasal Delivery.
    Bahadur S; Sachan N; Harwansh RK; Deshmukh R
    Curr Pharm Des; 2020; 26(12):1331-1344. PubMed ID: 32160843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical Discoveries on Multi-Target Approach to Manage Alzheimer's Disease.
    Batool A; Kamal MA; Rizvi SMD; Rashid S
    Curr Drug Metab; 2018; 19(8):704-713. PubMed ID: 29512457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of Current Strategies for Delivering Alzheimer's Disease Drugs across the Blood-Brain Barrier.
    Wong KH; Riaz MK; Xie Y; Zhang X; Liu Q; Chen H; Bian Z; Chen X; Lu A; Yang Z
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.
    Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
    Brain Res; 2008 Mar; 1200():159-68. PubMed ID: 18291351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal therapeutic strategies for management of Alzheimer's disease.
    Sood S; Jain K; Gowthamarajan K
    J Drug Target; 2014 May; 22(4):279-94. PubMed ID: 24404923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases.
    Hernando S; Gartziandia O; Herran E; Pedraz JL; Igartua M; Hernandez RM
    Nanomedicine (Lond); 2016 May; 11(10):1267-85. PubMed ID: 27077453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.